Skip to main content
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc. — Investor Relations & Filings

Ticker · SPRO ISIN · US84833T1034 LEI · 54930074G13LHWJT2323 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2017-12-15 Director's Dealing
Country US United States of America
Listing US SPRO

About Spero Therapeutics, Inc.

https://sperotherapeutics.com/

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. The company's primary mission is to address the significant unmet medical needs caused by antibiotic resistance. Its pipeline includes tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections (cUTIs), which has completed a Phase 3 trial. Spero Therapeutics leverages its expertise in chemistry and microbiology, alongside strategic partnerships, to advance its portfolio of innovative therapies for serious infections.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-12-15 English
FORM 4 SUBMISSION
Director's Dealing
2017-12-15 English
FORM 4 SUBMISSION
Director's Dealing
2017-12-15 English
FORM 4 SUBMISSION
Director's Dealing
2017-12-15 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock incentive plans. It includes details about the securities to be registered, the stock incentive plan, and legal opinions. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a mere announcement but a full registration statement.
2017-12-14 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its third quarter results for the period ended September 30, 2017, and that the press release is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length is 3283 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, an 8-K filing announcing earnings results with a press release attached is classified as an Earnings Release (ER).
2017-12-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.